je.st
news
Tag: patients
Death sentence no longer a given for melanoma patients Death sentence ...
2013-06-06 09:26:01| Biotech - Topix.net
Nathan Schwegman was just 25 when his doctor told him he had a 3 percent chance of surviving the melanoma that had spread into his lungs and spine, soon leaving him in so much pain he could hardly move.
Tags: longer
death
patients
sentence
Patients feeling at home, on call
2013-06-03 13:29:45| Industrial Machines - Topix.net
During a recent checkup, Thom Henkel's doc - University Hospitals' George Kikano - asked him to lean forward so he could inspect a blemish that appeared to be growing on his temple.
Tags: home
call
patients
feeling
Advaxis Reports Survival and New Analysis for ADXS-HPV in Patients...
2013-06-02 21:59:31| Logistics - Topix.net
The data were presented by Dr. Robert Petit, Chief Scientific Officer at Advaxis, at the 2013 American Society of Clinical Oncology Annual Meeting in Chicago, IL, on Sunday, June 2, 2013 .
Tags: in
reports
analysis
patients
Merck melanoma drug shrinks tumors in 38 percent of patients
2013-06-02 18:54:47| Biotech - Topix.net
A Merck & Co drug designed to unmask tumor cells and mobilize the immune system into fighting cancer helped shrink tumors in 38 percent of patients with advanced melanoma in an early-stage study, U.S. researchers said on Sunday.
Tags: of
drug
percent
patients
Merck Announces Presentation of Interim Data from Study Evaluating Lambrolizumab, an Investigational Anti-PD-1 Antibody, in Patients with Advanced Melanoma at ASCO 2013
2013-06-02 17:15:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. -Merck Expands Lambrolizumab Clinical Development Program- -Study Published Online in the New England Journal of Medicine- WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of preliminary results from an ongoing Phase IB expansion study evaluating the safety and efficacy of lambrolizumab (MK-3475), Mercks investigational antibody therapy targeting PD-1, in patients with advanced (inoperable and metastatic) melanoma. Language: English Contact HTML: MerckMedia Contacts:Ian McConnell, 973-901-5722Cathy Cantone, 908-327-3013orInvestor Contacts:Carol Ferguson, 908-500-1101Justin Holko, 609-915-8293 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
advanced
study
presentation
Sites : [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] next »